Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05005312 · ClinicalTrials.gov registry record · Phase 1

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

A Phase 1 study of Hepatic Impairment, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
2
Study locations

NCT05005312 is a Phase 1 study of Hepatic Impairment that has completed, run by Pfizer. The registered enrollment target is 17 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05005312, a Phase 1 study of Hepatic Impairment, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.

Conditions Studied

Hepatic Impairment

Interventions

  • DRUG Ritonavir
  • DRUG PF-07321332

Study Locations (2)

California

  • Orange County Research Center - Tustin

Minnesota

  • Prism Research LLC dba Nucleus Network - Saint Paul

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2021-08-31
Est. Completion 2021-12-07
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05005312

The ClinicalTrials.gov registry entry for NCT05005312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (53% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatic Impairment appearing as the primary indexed condition, and to 2 interventions - of which Ritonavir is the first listed.

NCT05005312 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05005312 about?

NCT05005312 is a clinical study titled "Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332". The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.

What is the current status of trial NCT05005312?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-08-31. Estimated completion is 2021-12-07.

What conditions does trial NCT05005312 study?

This clinical trial studies the following conditions: Hepatic Impairment.

What interventions are being tested in trial NCT05005312?

The interventions under investigation include: Ritonavir (DRUG), PF-07321332 (DRUG).

Who is sponsoring clinical trial NCT05005312?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05005312 being conducted?

This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatic Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatic Impairment

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.